Official finding is none of the 3 drugs were effective for COVID
JT
Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19 | NEJM
 |
Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19 | NEJM Abstract Background Early treatment to prevent severe coronavirus disease 2019 (Covid-19) is an important component of the comprehensive response to the severe acute respiratory syndrome coronaviru… http://www.nejm.org |
secondary analysis showed an aOR for an ED visit, hospitalization, or death of 0.58 (95% CI, 0.35 to 0.94) with metformin, 1.39 (95% CI, 0.72 to 2.69) with ivermectin, and 1.17 (95% CI, 0.57 to 2.40) with fluvoxamine. The aOR for hospitalization or death was 0.47 (95% CI, 0.20 to 1.11) with metformin, 0.73 (95% CI, 0.19 to 2.77) with ivermectin, and 1.11 (95% CI, 0.33 to 3.76) with fluvoxamine. The fluvoxamine arm was stopped early due to futility. The secondary analysis isn’t conclusive because the group couldn’t test its significance.
Joseph (Joe) E. Thornton, M.D., DFAPA
Clinical Associate Professor, Psychiatry
University of Florida College of Medicine
joethornton@ufl.edu
CONFIDENTIALITY NOTIFICATION: Please be advised! This e-mail message, including any attachments, has been created explicitly for the sole use of the intended recipient(s) and may contain confidential and privileged information. The materials in this message are private and may contain Protected Healthcare Information or other information of a sensitive nature. If you are not the intended recipient, be advised that any unauthorized use, disclosure, copying or the taking of any action in reliance on the contents of this information is strictly prohibited. If you have received this email in error, please immediately notify the sender via telephone or return mail. Any unauthorized review, use, disclosure, or distribution of such information is prohibited and will be upheld under the discretion of Federal and State law. If you have received this e-mail message in error and are not an intended recipient, please contact the sender via reply e-mail or phone and destroy all copies of the original message. Pursuant to ‘ FS 766.101, FS 395.0193, FS 395.0197, FS 766.1016 and other Statutes, this document is privileged and confidential. It is not subject to discovery. Please do NOT copy or release.
Gator Psychiatry 